MONITOR-CKD5 was a large, prospective, longitudinal, observational, 24-month, pharmaco-epidemiological study designed to examine the effectiveness and safety of IV HX575 (Binocrit® or epoetin alfa HEXAL®) in patients (n = 2 023 evaluable patients) with Stage V CKD and renal anaemia,...
The aim of this study was to develop an integrated pharmacokinetic and pharmacodynamic (PK/PD) model and assess the comparability between epoetin alfa HEXAL/Binocrit (HX575) and a comparator epoetin alfa by a model-based approach. PK/PD data鈥攊ncluding serum drug concentrations, reticulocyte ...
HX575, licensed under the brand names Binocrit, Epoetin Alfa Hexal, and Abseamed, was approved in 2007 as the first biosimilar recombinant human erythropoi... M Lissy,M Ode,K Roth - 《Drugs in R & D》 被引量: 33发表: 2011年 Evaluation of erythropoietin biosimilars Epotin, Hemax and ...
\\{PCN41\\} - Economic Evaluation of Epoetin Alfa Hexal (Binocrit) Compared to Darbepoetin Alfa (Aranesp) in the Treatment of Chemotherapy Induced Anemia (CIA) in Germanydoi:10.1016/j.jval.2013.08.439M. Turner and K. Walsh and J. Whitehouse...
The aim of this study was to develop an integrated pharmacokinetic and pharmacodynamic (PK/PD) model and assess the comparability between epoetin alfa HEXAL/Binocrit (HX575) and a comparator epoetin alfa by a model-based approach. PK/PD data—including serum drug concentrations, reticulocyte counts...